- Prescribing Advice for GPs - https://www.prescriber.org.uk -

SMC Update - September 2021

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Mercaptamine (Procysbi®) has been rejected for the treatment of proven nephropathic cystinosis. The submitting company's justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Amikacin liposomal nebuliser dispersion (Arikayce®) has been rejected for use in the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis. The submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.